BERKELEY, Calif.--(BUSINESS WIRE)--Sep 22, 2009 - Dynavax
Technologies Corporation (Nasdaq:DVAX) today announced that an
abstract with chronic kidney disease patient data for
HEPLISAVTM, an investigational adult hepatitis B
vaccine, will be presented at the 47th Annual Meeting of
the Infectious Disease Society of America (IDSA) in Philadelphia,
Pennsylvania, from October 29 through November 1, 2009.

HEPLISAV is a Phase 3 investigational adult hepatitis B vaccine
designed to provide increased, rapid protection with fewer doses
than current licensed vaccines. Over 2,500 individuals have been
vaccinated with HEPLISAV to date. Dynavax is developing HEPLISAV
for populations that are less responsive to current licensed
vaccines, including adults over 40 years of age, individuals with
chronic kidney disease, and others.

Dynavax Technologies Corporation, a clinical-stage
biopharmaceutical company, discovers and develops novel products to
prevent and treat infectious diseases. The Company's lead product
candidate is HEPLISAV, a Phase 3 investigational adult hepatitis B
vaccine designed to provide more rapid and increased protection
with fewer doses than current licensed vaccines. For more
information visit
www.dynavax.com.

Drugs.com provides accurate and independent information on more than 24,000 prescription drugs, over-the-counter medicines and natural products. This material is provided for educational purposes only and is not intended for medical advice, diagnosis or treatment.